Clinical smart watch finds success at identifying atrial fibrillation
As the use of wearable technology grows, smart watches are marketed across the globe to consumers as a way to monitor health. For some, they’re told by these… read more.
As the use of wearable technology grows, smart watches are marketed across the globe to consumers as a way to monitor health. For some, they’re told by these… read more.
Amgen announced new data reinforcing the safety and efficacy of Repatha (evolocumab) from the FOURIER Open Label Extension (OLE) [FOURIER-OLE] trial at the American Heart Association (AHA) Scientific… read more.
Medtronic plc announced that the FDA has approved the Symplicity Spyral renal denervation (RDN) system, also known as the Symplicity blood pressure procedure, for the treatment of hypertension…. read more.
The odds of prescribing the appropriate dose of statins—a medicine used to lower “bad” cholesterol levels—increased sixfold when automated referrals were made to pharmacy services, instead of relying… read more.
Patients treated with the investigative PCSK9 inhibitor recaticimab have achieved highly significant reducions in bad cholesterol, and they have done so with less frequent injections than patients treated… read more.
Low levels of Vitamin D have been shown to be associated with a higher risk of having a cardiac event, like a heart attack or stroke. For this… read more.
If pharmacists had a larger role in prescribing medications to control blood pressure, they could prevent more than 15 million heart attacks, nearly 8 million strokes and more… read more.
Edwards Lifesciences Corporation announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair (TEER) therapies, as well as… read more.
Abbott announced data from late-breaking presentations showing the impact of its minimally invasive heart devices in treating mitral and tricuspid valve disease . Data include findings from the… read more.
STEP-HFpEF was a randomised, controlled trial designed to find out whether semaglutide for 52 weeks could improve heart failure symptoms and physical function in obese, non-diabetic patients with… read more.
The results of the STEP-HFpEF trial point towards routine use of GLP-1 agonists in heart failure but this has to be balanced against conflicting guidelines and cost pressures… read more.
The results of the STEP-HFpEF trial showed statistically significant benefits “across the board” and these benefits were not due to weight loss alone, according to Vicky Ruszala, Specialist… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.